CN113056286B - 用于治疗胰腺炎的方法 - Google Patents
用于治疗胰腺炎的方法 Download PDFInfo
- Publication number
- CN113056286B CN113056286B CN201980073543.7A CN201980073543A CN113056286B CN 113056286 B CN113056286 B CN 113056286B CN 201980073543 A CN201980073543 A CN 201980073543A CN 113056286 B CN113056286 B CN 113056286B
- Authority
- CN
- China
- Prior art keywords
- pancreatitis
- antibody
- markers
- amino acid
- pancreatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510438979.9A CN120267815A (zh) | 2018-09-10 | 2019-09-09 | 用于治疗胰腺炎的方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729354P | 2018-09-10 | 2018-09-10 | |
| US62/729,354 | 2018-09-10 | ||
| PCT/US2019/050262 WO2020055768A1 (en) | 2018-09-10 | 2019-09-09 | Methods for treating pancreatitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510438979.9A Division CN120267815A (zh) | 2018-09-10 | 2019-09-09 | 用于治疗胰腺炎的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113056286A CN113056286A (zh) | 2021-06-29 |
| CN113056286B true CN113056286B (zh) | 2025-04-29 |
Family
ID=69776851
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980073543.7A Active CN113056286B (zh) | 2018-09-10 | 2019-09-09 | 用于治疗胰腺炎的方法 |
| CN202510438979.9A Pending CN120267815A (zh) | 2018-09-10 | 2019-09-09 | 用于治疗胰腺炎的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510438979.9A Pending CN120267815A (zh) | 2018-09-10 | 2019-09-09 | 用于治疗胰腺炎的方法 |
Country Status (13)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020055768A1 (en) | 2018-09-10 | 2020-03-19 | Cold Spring Harbor Laboratory | Methods for treating pancreatitis |
| US20250297027A1 (en) * | 2021-01-12 | 2025-09-25 | Yeda Research And Development Co. Ltd. | Antibodies to cancer glycosylation and uses thereof |
| CA3214598A1 (en) * | 2021-03-26 | 2022-09-29 | BioNTech SE | Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer |
| US12661076B2 (en) * | 2024-03-26 | 2026-06-23 | Hepatiq, Inc. | Determining pancreas disease using functional imaging |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0274264A1 (en) * | 1986-12-24 | 1988-07-13 | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. | Reverse passive particle agglutination reagent |
| CN102137681A (zh) * | 2008-08-08 | 2011-07-27 | 埃姆诺医药有限公司 | 抗胰腺癌抗体 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4471057A (en) * | 1981-06-30 | 1984-09-11 | The Wistar Institute | Detection of colorectal carcinoma |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| US5559103A (en) | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
| US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
| US7238715B2 (en) | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| EP1924276A4 (en) | 2005-08-05 | 2009-07-22 | Araim Pharmaceuticals Inc | Antiperspirant peptides and their uses |
| FI20070853A0 (fi) | 2007-11-09 | 2007-11-09 | Glykos Finland Oy | Glykaania sitovat monoklonaaliset vasta-aineet |
| WO2009094172A2 (en) | 2008-01-22 | 2009-07-30 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| PL2970422T3 (pl) | 2013-03-15 | 2018-09-28 | F.Hoffmann-La Roche Ag | Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania |
| CN105517561A (zh) | 2013-07-17 | 2016-04-20 | 阿拉伊姆药品公司 | 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物 |
| CN105764526B (zh) | 2013-08-26 | 2020-12-15 | 生物技术研发公司 | 编码抗唾液酸化路易斯a抗原的人抗体的核酸 |
| CN104623639A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | 白介素22二聚体在制备治疗胰腺炎药物中的应用 |
| RS60593B1 (sr) | 2014-01-24 | 2020-08-31 | Ngm Biopharmaceuticals Inc | Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| EP3448874A4 (en) * | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| WO2020055768A1 (en) | 2018-09-10 | 2020-03-19 | Cold Spring Harbor Laboratory | Methods for treating pancreatitis |
-
2019
- 2019-09-09 WO PCT/US2019/050262 patent/WO2020055768A1/en not_active Ceased
- 2019-09-09 US US17/274,783 patent/US12378320B2/en active Active
- 2019-09-09 SG SG11202102416SA patent/SG11202102416SA/en unknown
- 2019-09-09 CA CA3112382A patent/CA3112382A1/en active Pending
- 2019-09-09 EP EP19859491.3A patent/EP3849605A4/en not_active Withdrawn
- 2019-09-09 CN CN201980073543.7A patent/CN113056286B/zh active Active
- 2019-09-09 BR BR112021004444-2A patent/BR112021004444A2/pt not_active Application Discontinuation
- 2019-09-09 KR KR1020217008242A patent/KR20210073515A/ko not_active Ceased
- 2019-09-09 CN CN202510438979.9A patent/CN120267815A/zh active Pending
- 2019-09-09 AU AU2019337564A patent/AU2019337564A1/en not_active Abandoned
- 2019-09-09 JP JP2021513309A patent/JP7560445B2/ja active Active
- 2019-09-09 MX MX2021002761A patent/MX2021002761A/es unknown
-
2021
- 2021-03-09 CL CL2021000585A patent/CL2021000585A1/es unknown
- 2021-03-09 IL IL281343A patent/IL281343A/en unknown
-
2022
- 2022-01-13 CL CL2022000091A patent/CL2022000091A1/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0274264A1 (en) * | 1986-12-24 | 1988-07-13 | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. | Reverse passive particle agglutination reagent |
| CN102137681A (zh) * | 2008-08-08 | 2011-07-27 | 埃姆诺医药有限公司 | 抗胰腺癌抗体 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7560445B2 (ja) | 2024-10-02 |
| EP3849605A1 (en) | 2021-07-21 |
| AU2019337564A1 (en) | 2021-05-06 |
| CA3112382A1 (en) | 2020-03-19 |
| CL2021000585A1 (es) | 2021-08-13 |
| WO2020055768A1 (en) | 2020-03-19 |
| BR112021004444A2 (pt) | 2021-06-01 |
| JP2022500382A (ja) | 2022-01-04 |
| EP3849605A4 (en) | 2022-06-15 |
| CL2022000091A1 (es) | 2022-11-18 |
| CN120267815A (zh) | 2025-07-08 |
| KR20210073515A (ko) | 2021-06-18 |
| US20220049011A1 (en) | 2022-02-17 |
| US12378320B2 (en) | 2025-08-05 |
| IL281343A (en) | 2021-04-29 |
| MX2021002761A (es) | 2021-05-31 |
| SG11202102416SA (en) | 2021-04-29 |
| CN113056286A (zh) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022025071A (ja) | グリコシル化pd-1に対して特異的な抗体およびその使用方法 | |
| EP3360571B1 (en) | Antibodies binding to an intracellular prl-1 or prl-3 polypeptide | |
| JP7560445B2 (ja) | 膵炎を処置するための方法 | |
| KR20090039748A (ko) | 암의 치료, 진단 또는 검출을 위한 amigo-2 억제제 | |
| CN121248782A (zh) | 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法 | |
| AU2016261770B2 (en) | Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same | |
| CN109563154B (zh) | 抗帕多瓦因子ix抗体 | |
| JP2019505477A (ja) | Btn1a1に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用 | |
| US9790503B2 (en) | VHZ for diagnosis and treatment of cancer | |
| JP5756014B2 (ja) | がんの診断および治療のためのvhz | |
| CN111051346A (zh) | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 | |
| KR20180042423A (ko) | Cd37 의 검출을 위한 항체 및 검정 | |
| JP2017526916A (ja) | 癌の診断 | |
| JP2026063048A (ja) | がん免疫微小環境の調節物質およびそれによる予防・診断・治療的利用 | |
| JP2021531007A (ja) | Vistaに対する受容体 | |
| JP2023523145A (ja) | リポ蛋白(a)に対するイソ型非依存性抗体 | |
| US20220289840A1 (en) | Antibodies To Cell Adhesion Molecule-Related/Down-Regulated By Oncogenes (CDON) And Uses Thereof | |
| TW202246354A (zh) | 抗烯醇化酶1(eno1)抗體及其應用 | |
| US20250236683A1 (en) | Composition and method for inhibiting fibrosis | |
| RU2839356C2 (ru) | Способы лечения панкреатита | |
| WO2025217258A1 (en) | Nptx1 antibodies | |
| WO2025184480A2 (en) | Antibodies to cell adhesion molecule-related/down-regulated by oncogenes (cdon) and uses thereof | |
| HK40114573A (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
| Hinkofer | Distinction of vasculitis-associated ANCA subsets and their pathogenic role in a new mouse model with the humanized target antigen | |
| HK1252633B (en) | Antibodies binding to an intracellular prl-1 or prl-3 polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |